1. Home
  2. SMID vs IPHA Comparison

SMID vs IPHA Comparison

Compare SMID & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith-Midland Corporation

SMID

Smith-Midland Corporation

HOLD

Current Price

$33.18

Market Cap

151.1M

Sector

Industrials

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.42

Market Cap

141.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMID
IPHA
Founded
1960
1999
Country
United States
France
Employees
N/A
163
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.1M
141.7M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
SMID
IPHA
Price
$33.18
$1.42
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
7.0K
23.7K
Earning Date
04-14-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
62.76
N/A
EPS
2.36
N/A
Revenue
$93,446,000.00
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
$14.19
N/A
Revenue Growth
19.03
N/A
52 Week Low
$25.60
$1.18
52 Week High
$43.62
$2.63

Technical Indicators

Market Signals
Indicator
SMID
IPHA
Relative Strength Index (RSI) 57.33 47.01
Support Level $32.79 $1.18
Resistance Level $33.86 $1.80
Average True Range (ATR) 1.61 0.08
MACD 0.56 0.01
Stochastic Oscillator 93.75 27.91

Price Performance

Historical Comparison
SMID
IPHA

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: